Sign In
Last checked at 
5 Feb 2020 14:24
5th February 2020
Nuformix plc
("Nuformix" or "the Group"),
Director Dealing
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs was notified that on the 24th January 2020, David Tapolczay, Non-Executive Chairman of the Group, sold 650,000 Ordinary Shares ("Ordinary Shares") in the Group at a price of 8.7p per share.
Following the transaction, David Tapolczay's total interest in the Group has decreased to 44,305,000 Ordinary Shares, representing 9.04% of the Group's issued share capital.
1
| Details of the person discharging managerial responsibilities.
| ||||
a)
| Name
| David Joszef Tapolczay | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Non-Executive Chairman | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Nuformix plc | |||
b)
| LEI
| 2138003XG3H3I2J3BJ24
| |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 0.1p each | |||
Identification code | GB00BYW79Y38 | ||||
b)
| Nature of the transaction
| Disposal of ordinary Shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
8.7p | 650,000 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | 650,000 | ||||
- Price | 8.7p | ||||
e)
| Date of the transaction
| 24/01/2020 | |||
f)
| Place of the transaction
| Standard List, London Stock Exchange | |||
Market Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.
Enquiries:
Nuformix plc Dr Dan Gooding, Chief Executive Officer Email: info@nuformix.com
|
+44 (0)1223 627222
|
Novum Securities Limited Jon Belliss / Colin Rowbury |
+44 (0)20 7399 9427 |
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.
Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.
Follow the stocks
